» Articles » PMID: 22678941

'You Never Told Me I Would Turn into a Gambler': a First Person Account of Dopamine Agonist--induced Gambling Addiction in a Patient with Restless Legs Syndrome

Overview
Journal BMJ Case Rep
Specialty General Medicine
Date 2012 Jun 9
PMID 22678941
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Dopaminergic agents are commonly used and effective treatments for restless legs syndrome (RLS), a disabling sensorimotor disorder. Less known are some of the potentially disabling side effects of these treatments, particularly iatrogenic gambling addiction, as is described here. Here the authors present a 62-year-old man, with a 20-year history of RLS, who developed gambling addiction while on dopaminergic treatment. He was not forewarned of this side effect, nor was he ever screened for gambling behaviours prior to or during treatment. Eight months after discontinuation of dopaminergic treatment and after 10 sessions of cognitive-behavioural therapy for gambling addiction, his gambling behaviours have partially resolved. To our knowledge, this is the first ever first person account of this condition. To prevent the devastating consequences of gambling addiction or to minimise its impact by early intervention, the authors call for clinicians involved in treatment of RLS to follow these simple measures: screen patients for gambling behaviours prior to the onset and during dopaminergic treatment; forewarn patients of this potential side effect; and if patients screen positive, refer them to specialist gambling treatment services, in addition to making necessary changes to their medication regime.

Citing Articles

Treatment of harmful gambling: a scoping review of United Kingdom-based intervention research.

Seel C, Jones M, Christensen D, May R, Hoon A, Dymond S BMC Psychiatry. 2024; 24(1):392.

PMID: 38783231 PMC: 11112764. DOI: 10.1186/s12888-024-05843-8.


Restless legs syndrome: Over 50 years of European contribution.

Khachatryan S, Ferri R, Fulda S, Garcia-Borreguero D, Manconi M, Muntean M J Sleep Res. 2022; 31(4):e13632.

PMID: 35808955 PMC: 9542244. DOI: 10.1111/jsr.13632.


Increased Risk for New-Onset Psychiatric Adverse Events in Patients With Newly Diagnosed Primary Restless Legs Syndrome Who Initiate Treatment With Dopamine Agonists: A Large-Scale Retrospective Claims Matched-Cohort Analysis.

Hankin C, Lee D, Garcia-Borreguero D, Wang Z J Clin Sleep Med. 2019; 15(9):1225-1232.

PMID: 31538593 PMC: 6760417. DOI: 10.5664/jcsm.7908.


Dopamine Agonists and Impulse Control Disorders: A Complex Association.

Grall-Bronnec M, Victorri-Vigneau C, Donnio Y, Leboucher J, Rousselet M, Thiabaud E Drug Saf. 2017; 41(1):19-75.

PMID: 28861870 PMC: 5762774. DOI: 10.1007/s40264-017-0590-6.

References
1.
Gamaldo C, Earley C . Restless legs syndrome: a clinical update. Chest. 2006; 130(5):1596-604. DOI: 10.1378/chest.130.5.1596. View

2.
Dang D, Cunnington D, Swieca J . The emergence of devastating impulse control disorders during dopamine agonist therapy of the restless legs syndrome. Clin Neuropharmacol. 2011; 34(2):66-70. DOI: 10.1097/WNF.0b013e31820d6699. View

3.
Hogl B, Kiechl S, Willeit J, Saletu M, Frauscher B, Seppi K . Restless legs syndrome: a community-based study of prevalence, severity, and risk factors. Neurology. 2005; 64(11):1920-4. DOI: 10.1212/01.WNL.0000163996.64461.A3. View

4.
Barns Neurauter M, Rickards H, Cavanna A . The prevalence and clinical characteristics of pathological gambling in Parkinson's disease: an evidence-based review. Funct Neurol. 2010; 25(1):9-13. View

5.
Quickfall J, Suchowersky O . Pathological gambling associated with dopamine agonist use in restless legs syndrome. Parkinsonism Relat Disord. 2007; 13(8):535-6. DOI: 10.1016/j.parkreldis.2006.10.001. View